Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2019.00723
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Bevacizumab Improves Survival in Metastatic Colorectal Cancer Patients With Primary Tumor Resection: A Meta-Analysis

Scientific Reports
Multidisciplinary
2019English

The Impact of Microsatellite Instability Status and Sidedness of the Primary Tumor on the Effect of Cetuximab-Containing Chemotherapy in Patients With Metastatic Colorectal Cancer

Journal of Cancer
Oncology
2017English

PCN22 Safety Profile of Bevacizumab in Metastatic Colorectal Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Impact of Primary Tumour Location on Efficacy of Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-Ras Mutation Status: Analysis of a Phase III Study of Bevacizumab With Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Oncologist
Cancer ResearchMedicineOncology
2009English

Bevacizumab May Overcome Clinical Tumor Drug Resistance to Irinotecan Based Chemotherapy in Patients With Metastatic Colorectal Cancer: Case Report

The Open Colorectal Cancer Journal
2010English

PTEN Loss of Expression Predicts Cetuximab Efficacy in Metastatic Colorectal Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2007English

Hypertension and Overall Survival in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Containing Chemotherapy

British Journal of Cancer
Cancer ResearchOncology
2011English

Adverse Events Associated With Bevacizumab and Chemotherapy in Older Patients With Metastatic Colorectal Cancer

Clinical Colorectal Cancer
OncologyGastroenterology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy